Pathological Changes in Alzheimer's Disease Analyzed Using Induced Pluripotent Stem Cell-Derived Human Microglia-Like...

Area of Science:

• Neuroscience
• Immunology
• Stem Cell Biology

Background:

• Microglia are key innate immune cells in the brain; their dysfunction is linked to central nervous system diseases.
• Obtaining primary human microglia is experimentally challenging, hindering research into their role in complex diseases.
• Human stem cell-derived microglia present a valuable alternative for disease modeling and therapeutic development.

Purpose of the Study:

• To establish a reliable method for deriving human microglial-like cells (iMGLs) from induced pluripotent stem cells (iPSCs).
• To characterize iMGLs expressing microglia-specific markers (IBA1, TMEM119) and their response to lipopolysaccharide (LPS).
• To compare the functional and inflammatory profiles of iMGLs from Alzheimer's disease (AD) patients versus cognitive normal controls (CNCs).

Main Methods:

• Generation of induced microglial-like cells (iMGLs) from human induced pluripotent stem cells (iPSCs).
• Assessment of microglia-specific marker expression (IBA1, TMEM119).
• Functional assays including phagocytosis, lipopolysaccharide (LPS) stimulation, cell viability, and cytokine analysis (TNF-α, IL-6, IL-10).

Main Results:

• iMGLs successfully expressed microglia-specific markers and responded to LPS stimulation.
• Alzheimer's disease-derived iMGLs (AD-iMGLs) exhibited enhanced phagocytic activity compared to control iMGLs.
• AD-iMGLs showed increased secretion of inflammatory cytokines (TNF-α, IL-6, IL-10) upon LPS stimulation and greater resistance to LPS-induced cell death.

Conclusions:

• AD-iMGLs display distinct inflammatory characteristics and functional alterations relevant to Alzheimer's disease pathogenesis.
• These iMGLs serve as a valuable in vitro model for studying microglial dysfunction in AD.
• The developed iMGL model can facilitate drug screening and mechanistic studies for Alzheimer's disease therapies.